On October 10, 2025, Piper Sandler raised its price target for AbbVie Inc (ABBV) from $231.00 to $284.00 while maintaining an 'Overweight' rating, signaling increased analyst confidence in the company's outlook. This major analyst action comes as ABBV trades at $231.36 (+0.29%) during live trading, following a week of moderate volatility. No significant company-specific operational news or earnings announcements were reported today, and the next scheduled financial results are set for October 31, 2025. The positive analyst update stands out against a broadly negative market backdrop, with major indices down over 1%, suggesting ABBV's price movement is being supported by favorable analyst sentiment rather than broader market weakness.